A Phase 3 interventional study of V116 and PPSV23 in Pneumococcal Disease, sponsored by Merck Sharp & Dohme LLC. Completed at 8 sites in Japan. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-02.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections — 1 open to participants now, 2 under way, 2 of them phase 3. Pneumococcal 21-Valent Conjugate Vaccine · Pneumococcal Infections.
Among the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 8th largest by enrollment, is one of 2 that started in 2023, is one of 9 in phase 3, and was the 6th registered.
299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.
Browse Pneumococcal Infections studies →1 of the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections is open now, in 4 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Honduras, Puerto Rico and 1 more country
Ages 42 days–89 days · Healthy volunteers
By country, each count listing its studies:
Pneumococcal 21-Valent Conjugate Vaccine: first FDA approval 2024 (CAPVAXIVE). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 2 started in 2023.
This study's enrollment of 450 is above the median of 379 across 254 interventional studies indexed under Pneumococcal Infections.
Median enrollment 1,075 across the 10 interventional studies. Of the 8 that completed or were terminated, 8 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 3 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
43 studies in Pneumococcal Infections by Merck & Co., Inc: 1 open now, 1 under way, none of them phase 3. Of 42 finished, 40 (95%) have results posted.
Among the 43 studies in Pneumococcal Infections by Merck & Co., Inc, this one is the 24th largest by enrollment, is one of 2 that started in 2023, is one of 31 in phase 3, and was the 40th registered.
Merck & Co., Inc’s Pneumococcal Infections studies by the year they started, since 2005.
2 of the studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06838000Phase 3Sanofi Pasteur, a Sanofi CompanyStudy of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents | 2026-12-01 |
| NCT07348692Phase 3SanofiLot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age | 2027-06-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 43 in Pneumococcal Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a phase 3, randomized, double-blind, active comparator-controlled study of the safety, tolerability, and immunogenicity of V116 in pneumococcal vaccine-naïve Japanese adults 65 years of age and older. The polyvalent (23-valent) pneumococcal vaccine, PPSV23, is the active comparator. In addition to studying safety/tolerability, it is hypothesized that, at 30 days postvaccination, the immunogenicity of V116 is noninferior to PPSV23 for the 12 common serotypes in V116 and PPSV23 and the cross-reactive serotype 15B in V116, and that the immunogenicity of V116 is superior to PPSV23 for the unique serotype 15C in V116. It is also hypothesized that V116 is superior to PPSV23 in the percentage of participants with ≥4-fold rise from baseline in the 8 unique V116 serotypes (except for 15C), as measured by serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive a single intramuscular (IM) injection of V116 on Day 1.
Biological: V116
Participants receive a single IM injection of PPSV23 on Day 1.
Biological: PPSV23
Sterile 0.5 mL solution in prefilled syringe containing 4 μg of each pneumococcal polysaccharide (PnPs) antigen 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B.
Also known as: Pneumococcal 21-valent Conjugate Vaccine
Drug page: 23-valent pneumococcal capsular polysaccharide vaccine
Sterile 0.5 mL solution in prefilled syringe containing 25 μg of each PnPs antigen 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.
Also known as: PNEUMOVAX™23
Percentage of Participants With Solicited Injection-site Adverse Events (AEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The solicited injection-site AEs assessed were redness/erythema, swelling, and tenderness/pain.
Time frame: Up to 5 days postvaccination
Percentage of Participants With Solicited Systemic AEs
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The solicited systemic AEs were muscle pain/myalgia, headache, and tiredness/fatigue.
Time frame: Up to 5 days postvaccination
Percentage of Participants With Vaccine-related Serious AEs (SAEs)
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event. SAEs that were reported to be at least possibly related by the investigator to study vaccination were summarized.
Time frame: Up to 30 days postvaccination
Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs)
The serotype-specific OPA GMTs for the 12 common serotypes contained in V116 and PPSV23, the unique serotype 15C in V116, and the cross-reactive serotype 15B were determined using the multiplex opsonophagocytic assay (MOPA).
Time frame: Day 30 postvaccination
Percentage of Participants With ≥4-fold Rise From Baseline in Serotype-specific OPAs (Unique to V116)
The percentage of participants with ≥4-fold rise from baseline in serotype-specific OPAs for the 8 unique serotypes contained in V116 (except for 15C) were determined.
Time frame: Baseline (Day 1) and Day 30 postvaccination
Serotype-specific OPA GMTs (Unique Serotypes)
The serotype-specific OPA GMTs for the 8 unique serotypes contained in V116 (except for serotype 15C) and the cross-reactive serotype 6C in V116 were determined using MOPA.
Time frame: Day 30 postvaccination
Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs)
The GMCs for serotype-specific IgG antibodies were determined using pneumococcal electrochemiluminescence (PnECL).
Time frame: Day 30 postvaccination
Serotype-specific Geometric Mean Fold Rise (GMFR) in OPA GMT
The GMFR from baseline in serotype-specific OPA GMTs was determined using MOPA. GMFR is defined as the geometric mean of the ratio of concentration at Day 30 after vaccination divided by concentration at baseline.
Time frame: Baseline (Day 1) and Day 30 postvaccination
Serotype-specific GMFR in IgG GMCs
The GMFR from baseline in GMCs for serotype-specific IgG antibodies was determined using PnECL. GMFR is defined as the geometric mean of the ratio of concentration at Day 30 after vaccination divided by concentration at baseline.
Time frame: Baseline (Day 1) and Day 30 postvaccination
Percentage of Participants With ≥4-fold Rise From Baseline in Serotype-specific OPA GMTs (All Serotypes)
Activity for the serotypes contained in V116 and PPSV23 were determined using MOPA. The percentage of participants who had ≥4-fold rise in OPA titers were calculated from baseline to postvaccination.
Time frame: Baseline (Day 1) and Day 30 postvaccination
Percentage of Participants With ≥4-fold Rise From Baseline in Serotype-specific IgG GMCs (All Serotypes)
Activity for the serotypes contained in V116 and PPSV23 were determined using PnECL. The percentage of participants who had ≥4-fold rise in IgG titers were calculated from baseline to postvaccination.
Time frame: Baseline (Day 1) and Day 30 postvaccination
| Milestone | V116 | PPSV23 |
|---|---|---|
| Started | 225 | 225 |
| Completed | 225 | 225 |
| Not completed | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The solicited injection-site AEs assessed were redness/erythema, swelling, and tenderness/pain.
| Percentage of participants | V116 | PPSV23 |
|---|---|---|
| Percentage of Participants With Solicited Injection-site Adverse Events (AEs) | 32.9 | 39.1 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The solicited systemic AEs were muscle pain/myalgia, headache, and tiredness/fatigue.
| Percentage of participants | V116 | PPSV23 |
|---|---|---|
| Percentage of Participants With Solicited Systemic AEs | 17.3 | 16.4 |
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event. SAEs that were reported to be at least possibly related by the investigator to study vaccination were summarized.
| Percentage of participants | V116 | PPSV23 |
|---|---|---|
| Percentage of Participants With Vaccine-related Serious AEs (SAEs) | 0.0 | 0.0 |
The serotype-specific OPA GMTs for the 12 common serotypes contained in V116 and PPSV23, the unique serotype 15C in V116, and the cross-reactive serotype 15B were determined using the multiplex opsonophagocytic assay (MOPA).
| Titers | V116 | PPSV23 |
|---|---|---|
| Day 30, Serotype 3 | 155.1 (133.6 to 180.1) | 170.8 (143.9 to 202.9) |
| Day 30, Serotype 7F | 2675.1 (2312.9 to 3094.0) | 2411.4 (2054.5 to 2830.2) |
| Day 30, Serotype 8 | 1293.3 (1133.8 to 1475.2) | 1142.4 (988.3 to 1320.4) |
| Day 30, Serotype 9N | 2844.8 (2492.7 to 3246.6) | 2710.5 (2297.6 to 3197.6) |
| Day 30, Serotype 10A | 1591.2 (1367.4 to 1851.7) | 880.2 (690.1 to 1122.6) |
| Day 30, Serotype 11A | 1269.6 (1057.6 to 1524.1) | 887.9 (748.3 to 1053.4) |
| Day 30, Serotype 12F | 968.5 (792.5 to 1183.6) | 503.7 (383.8 to 661.0) |
| Day 30, Serotype 17F | 3138.1 (2673.0 to 3684.2) | 1860.3 (1551.8 to 2230.1) |
| Day 30, Serotype 19A | 1338.4 (1144.3 to 1565.4) | 1140.7 (925.1 to 1406.5) |
| Day 30, Serotype 20A | 2617.2 (2212.9 to 3095.5) | 1731.5 (1474.1 to 2033.7) |
| Day 30, Serotype 22F | 1830.9 (1562.4 to 2145.6) | 1295.5 (1072.6 to 1564.8) |
| Day 30, Serotype 33F | 7692.4 (6349.4 to 9319.4) | 8610.8 (7029.9 to 10547.1) |
| Day 30, Serotype 15C | 2488.5 (1993.5 to 3106.6) | 1185.0 (954.1 to 1471.7) |
| Day 30, Serotype 15B | 2081.1 (1675.0 to 2585.7) | 1479.7 (1218.0 to 1797.5) |
| Baseline, Serotype 3 | 14.2 (12.5 to 16.1) | 14.9 (13.1 to 17.0) |
| Baseline, Serotype 7F | 243.9 (190.8 to 311.7) | 217.6 (168.8 to 280.4) |
| Baseline, Serotype 8 | 48.8 (38.3 to 62.3) | 46.3 (36.7 to 58.5) |
| Baseline, Serotype 9N | 383.1 (313.3 to 468.4) | 383.2 (314.6 to 466.8) |
| Baseline, Serotype 10A | 131.5 (101.3 to 170.6) | 103.5 (77.4 to 138.5) |
| Baseline, Serotype 11A | 75.2 (55.9 to 101.3) | 91.2 (68.3 to 121.7) |
| Baseline, Serotype 12F | 18.1 (14.7 to 22.3) | 19.2 (15.6 to 23.7) |
| Baseline, Serotype 17F | 285.8 (225.7 to 361.8) | 226.8 (181.0 to 284.1) |
| Baseline, Serotype 19A | 188.1 (151.9 to 232.8) | 179.7 (143.4 to 225.1) |
| Baseline, Serotype 20A | 460.0 (384.4 to 550.6) | 421.1 (348.9 to 508.1) |
| Baseline, Serotype 22F | 179.9 (138.0 to 234.7) | 167.9 (128.0 to 220.3) |
| Baseline, Serotype 33F | 1236.7 (1048.1 to 1459.3) | 1198.9 (1004.3 to 1431.3) |
| Baseline, Serotype 15C | 110.0 (85.2 to 142.1) | 102.6 (79.4 to 132.4) |
| Baseline, Serotype 15B | 243.3 (194.6 to 304.1) | 251.7 (199.7 to 317.2) |
The percentage of participants with ≥4-fold rise from baseline in serotype-specific OPAs for the 8 unique serotypes contained in V116 (except for 15C) were determined.
| Percentage of Participants | V116 | PPSV23 |
|---|---|---|
| Serotype 6A | 72.8 | 45.3 |
| Serotype 15A | 59.7 | 26.0 |
| Serotype 16F | 50.3 | 11.9 |
| Serotype 23A | 57.6 | 27.9 |
| Serotype 23B | 82.1 | 43.7 |
| Serotype 24F | 42.9 | 16.0 |
| Serotype 31 | 70.3 | 13.1 |
| Serotype 35B | 52.9 | 6.0 |
The serotype-specific OPA GMTs for the 8 unique serotypes contained in V116 (except for serotype 15C) and the cross-reactive serotype 6C in V116 were determined using MOPA.
| Titers | V116 | PPSV23 |
|---|---|---|
| Serotype 6A | 1263.8 (1036.6 to 1540.7) | 641.8 (507.0 to 812.4) |
| Serotype 15A | 2752.3 (2319.8 to 3265.5) | 832.2 (687.4 to 1007.6) |
| Serotype 16F | 4094.8 (3574.8 to 4690.4) | 1183.9 (987.2 to 1419.7) |
| Serotype 23A | 2107.5 (1702.3 to 2609.1) | 729.2 (556.8 to 955.0) |
| Serotype 23B | 1359.0 (1086.7 to 1699.5) | 202.2 (146.5 to 279.2) |
| Serotype 24F | 2521.9 (2246.2 to 2831.4) | 1043.8 (878.1 to 1240.7) |
| Serotype 31 | 2095.4 (1746.3 to 2514.2) | 260.7 (200.9 to 338.2) |
| Serotype 35B | 4758.1 (4146.5 to 5459.9) | 1051.4 (886.6 to 1246.9) |
The GMCs for serotype-specific IgG antibodies were determined using pneumococcal electrochemiluminescence (PnECL).
| µg/mL | V116 | PPSV23 |
|---|---|---|
| Serotype 3 | 0.54 (0.47 to 0.61) | 0.58 (0.51 to 0.67) |
| Serotype 7F | 6.12 (5.13 to 7.31) | 4.25 (3.50 to 5.14) |
| Serotype 8 | 8.13 (7.01 to 9.42) | 6.72 (5.87 to 7.71) |
| Serotype 9N | 7.49 (6.23 to 9.01) | 5.44 (4.55 to 6.50) |
| Serotype 10A | 8.21 (6.64 to 10.15) | 3.84 (3.09 to 4.79) |
| Serotype 11A | 6.00 (5.09 to 7.08) | 3.02 (2.59 to 3.52) |
| Serotype 12F | 1.55 (1.23 to 1.95) | 0.66 (0.52 to 0.84) |
| Serotype 17F | 10.48 (8.77 to 12.52) | 5.08 (4.32 to 5.98) |
| Serotype 19A | 5.70 (4.80 to 6.76) | 4.87 (4.07 to 5.83) |
| Serotype 20A | 15.61 (13.20 to 18.47) | 9.78 (8.09 to 11.83) |
| Serotype 22F | 2.84 (2.28 to 3.52) | 1.39 (1.14 to 1.69) |
| Serotype 33F | 13.93 (11.92 to 16.27) | 12.67 (10.90 to 14.74) |
| Serotype 6A | 3.42 (2.74 to 4.26) | 1.64 (1.33 to 2.02) |
| Serotype 15A | 9.98 (8.14 to 12.25) | 1.64 (1.35 to 1.98) |
| Serotype 15C | 9.87 (7.95 to 12.26) | 4.55 (3.69 to 5.60) |
| Serotype 16F | 3.07 (2.56 to 3.68) | 0.37 (0.31 to 0.43) |
| Serotype 23A | 2.00 (1.60 to 2.51) | 0.32 (0.27 to 0.39) |
| Serotype 23B | 4.22 (3.58 to 4.99) | 1.65 (1.37 to 1.98) |
| Serotype 24F | 7.79 (6.26 to 9.71) | 0.41 (0.35 to 0.47) |
| Serotype 31 | 2.57 (2.16 to 3.07) | 0.40 (0.34 to 0.46) |
| Serotype 35B | 14.19 (12.01 to 16.76) | 1.38 (1.19 to 1.60) |
| Serotype 6C | 1.19 (0.97 to 1.46) | 0.50 (0.42 to 0.59) |
| Serotype 15B | 10.15 (8.35 to 12.35) | 9.86 (8.40 to 11.59) |
The GMFR from baseline in serotype-specific OPA GMTs was determined using MOPA. GMFR is defined as the geometric mean of the ratio of concentration at Day 30 after vaccination divided by concentration at baseline.
| Ratio | V116 | PPSV23 |
|---|---|---|
| Serotype 3 | 7.2 (6.1 to 8.5) | 7.2 (6.1 to 8.5) |
| Serotype 7F | 10.0 (8.0 to 12.6) | 9.8 (8.0 to 12.1) |
| Serotype 8 | 20.6 (16.4 to 25.8) | 19.1 (15.5 to 23.7) |
| Serotype 9N | 6.9 (5.6 to 8.5) | 6.6 (5.3 to 8.1) |
| Serotype 10A | 10.1 (8.2 to 12.4) | 7.6 (5.9 to 9.9) |
| Serotype 11A | 13.6 (10.5 to 17.7) | 7.3 (5.7 to 9.4) |
| Serotype 12F | 32.2 (25.7 to 40.3) | 17.1 (13.2 to 22.1) |
| Serotype 17F | 9.8 (7.8 to 12.4) | 7.1 (5.9 to 8.6) |
| Serotype 19A | 6.7 (5.5 to 8.1) | 5.8 (4.8 to 6.9) |
| Serotype 20A | 5.6 (4.7 to 6.6) | 4.1 (3.4 to 4.8) |
| Serotype 22F | 8.9 (6.9 to 11.5) | 6.9 (5.4 to 8.8) |
| Serotype 33F | 6.4 (5.2 to 7.8) | 7.3 (6.0 to 8.8) |
| Serotype 6A | 9.4 (7.5 to 11.6) | 3.7 (3.0 to 4.5) |
| Serotype 15A | 6.7 (5.3 to 8.5) | 2.0 (1.6 to 2.4) |
| Serotype 15C | 19.1 (15.2 to 24.1) | 9.3 (7.4 to 11.7) |
| Serotype 16F | 4.7 (4.0 to 5.6) | 1.5 (1.4 to 1.7) |
| Serotype 23A | 5.9 (4.2 to 8.2) | 1.8 (1.4 to 2.4) |
| Serotype 23B | 26.2 (20.5 to 33.6) | 4.2 (3.3 to 5.4) |
| Serotype 24F | 3.8 (3.1 to 4.6) | 1.5 (1.2 to 1.8) |
| Serotype 31 | 13.6 (10.6 to 17.3) | 1.4 (1.2 to 1.6) |
| Serotype 35B | 5.5 (4.6 to 6.5) | 1.2 (1.0 to 1.3) |
| Serotype 6C | 2.9 (2.4 to 3.7) | 2.0 (1.7 to 2.3) |
| Serotype 15B | 7.4 (5.7 to 9.5) | 4.8 (3.7 to 6.2) |
The GMFR from baseline in GMCs for serotype-specific IgG antibodies was determined using PnECL. GMFR is defined as the geometric mean of the ratio of concentration at Day 30 after vaccination divided by concentration at baseline.
| Ratio | V116 | PPSV23 |
|---|---|---|
| Serotype 3 | 5.0 (4.5 to 5.7) | 5.1 (4.5 to 5.8) |
| Serotype 7F | 12.1 (10.2 to 14.3) | 8.3 (7.1 to 9.7) |
| Serotype 8 | 11.6 (9.8 to 13.7) | 9.8 (8.4 to 11.3) |
| Serotype 9N | 11.8 (9.8 to 14.3) | 9.8 (8.4 to 11.5) |
| Serotype 10A | 11.4 (9.7 to 13.4) | 6.4 (5.5 to 7.4) |
| Serotype 11A | 8.0 (6.8 to 9.4) | 3.9 (3.5 to 4.4) |
| Serotype 12F | 11.9 (9.8 to 14.6) | 6.3 (5.2 to 7.5) |
| Serotype 17F | 12.9 (10.9 to 15.2) | 7.0 (6.1 to 8.1) |
| Serotype 19A | 5.1 (4.3 to 5.9) | 4.2 (3.7 to 4.9) |
| Serotype 20A | 9.5 (8.1 to 11.2) | 6.2 (5.4 to 7.2) |
| Serotype 22F | 10.7 (8.9 to 12.9) | 5.7 (4.8 to 6.6) |
| Serotype 33F | 8.7 (7.4 to 10.2) | 7.7 (6.6 to 8.9) |
| Serotype 6A | 10.4 (8.7 to 12.5) | 4.1 (3.6 to 4.7) |
| Serotype 15A | 14.0 (11.8 to 16.5) | 2.7 (2.4 to 3.1) |
| Serotype 15C | 14.3 (11.8 to 17.3) | 6.9 (5.9 to 8.1) |
| Serotype 16F | 12.8 (11.0 to 14.9) | 1.6 (1.5 to 1.7) |
| Serotype 23A | 12.0 (10.1 to 14.4) | 2.0 (1.8 to 2.2) |
| Serotype 23B | 8.6 (7.5 to 10.0) | 3.1 (2.8 to 3.5) |
| Serotype 24F | 18.0 (15.2 to 21.2) | 1.1 (1.0 to 1.1) |
| Serotype 31 | 9.1 (8.0 to 10.5) | 1.5 (1.3 to 1.6) |
| Serotype 35B | 12.7 (10.8 to 14.8) | 1.1 (1.0 to 1.1) |
| Serotype 6C | 2.7 (2.3 to 3.2) | 1.3 (1.2 to 1.4) |
| Serotype 15B | 6.8 (5.7 to 8.2) | 7.3 (6.3 to 8.6) |
Activity for the serotypes contained in V116 and PPSV23 were determined using MOPA. The percentage of participants who had ≥4-fold rise in OPA titers were calculated from baseline to postvaccination.
| Percentage of Participants | V116 | PPSV23 |
|---|---|---|
| Serotype 3 | 73.8 (66.9 to 79.9) | 71.3 (64.4 to 77.5) |
| Serotype 7F | 68.5 (61.9 to 74.7) | 69.6 (63.0 to 75.6) |
| Serotype 8 | 79.8 (73.8 to 85.0) | 81.0 (75.1 to 86.1) |
| Serotype 9N | 57.6 (50.0 to 65.0) | 58.8 (51.1 to 66.1) |
| Serotype 10A | 69.3 (62.4 to 75.6) | 59.7 (52.4 to 66.7) |
| Serotype 11A | 69.3 (62.4 to 75.6) | 55.8 (48.6 to 62.9) |
| Serotype 12F | 84.3 (78.7 to 88.8) | 74.3 (67.7 to 80.1) |
| Serotype 17F | 66.1 (58.8 to 72.9) | 62.6 (55.3 to 69.5) |
| Serotype 19A | 58.1 (51.2 to 64.7) | 61.0 (54.1 to 67.6) |
| Serotype 20A | 54.1 (47.1 to 61.1) | 42.3 (35.3 to 49.6) |
| Serotype 22F | 62.0 (55.0 to 68.6) | 52.3 (45.1 to 59.4) |
| Serotype 33F | 58.0 (51.1 to 64.7) | 63.7 (56.9 to 70.2) |
| Serotype 6A | 72.8 (65.8 to 79.1) | 45.3 (38.0 to 52.6) |
| Serotype 15A | 59.7 (52.1 to 66.9) | 26.0 (19.6 to 33.3) |
| Serotype 15C | 81.0 (74.9 to 86.2) | 65.4 (58.2 to 72.2) |
| Serotype 16F | 50.3 (43.1 to 57.4) | 11.9 (7.8 to 17.2) |
| Serotype 23A | 57.6 (49.1 to 65.8) | 27.9 (19.8 to 37.2) |
| Serotype 23B | 82.1 (76.1 to 87.1) | 43.7 (36.7 to 50.9) |
| Serotype 24F | 42.9 (35.9 to 50.1) | 16.0 (10.9 to 22.3) |
| Serotype 31 | 70.3 (63.8 to 76.3) | 13.1 (8.9 to 18.4) |
| Serotype 35B | 52.9 (46.1 to 59.7) | 6.0 (3.2 to 10.0) |
| Serotype 6C | 34.2 (27.6 to 41.1) | 25.4 (19.5 to 32.1) |
| Serotype 15B | 67.2 (60.0 to 73.9) | 54.6 (47.1 to 61.9) |
Activity for the serotypes contained in V116 and PPSV23 were determined using PnECL. The percentage of participants who had ≥4-fold rise in IgG titers were calculated from baseline to postvaccination.
| Percentage of Participants | V116 | PPSV23 |
|---|---|---|
| Serotype 3 | 56.4 (49.7 to 63.0) | 59.6 (52.8 to 66.0) |
| Serotype 7F | 77.8 (71.8 to 83.0) | 70.7 (64.2 to 76.5) |
| Serotype 8 | 78.7 (72.7 to 83.8) | 78.7 (72.7 to 83.8) |
| Serotype 9N | 72.9 (66.6 to 78.6) | 75.1 (68.9 to 80.6) |
| Serotype 10A | 79.1 (73.2 to 84.2) | 61.8 (55.1 to 68.2) |
| Serotype 11A | 69.3 (62.9 to 75.3) | 44.9 (38.3 to 51.6) |
| Serotype 12F | 73.3 (67.0 to 79.0) | 56.9 (50.1 to 63.5) |
| Serotype 17F | 82.7 (77.1 to 87.4) | 69.3 (62.9 to 75.3) |
| Serotype 19A | 49.3 (42.6 to 56.1) | 47.1 (40.4 to 53.9) |
| Serotype 20A | 75.1 (68.9 to 80.6) | 59.6 (52.8 to 66.0) |
| Serotype 22F | 71.6 (65.2 to 77.4) | 56.9 (50.1 to 63.5) |
| Serotype 33F | 71.6 (65.2 to 77.4) | 73.3 (67.0 to 79.0) |
| Serotype 6A | 76.4 (70.3 to 81.8) | 45.8 (39.1 to 52.5) |
| Serotype 15A | 80.9 (75.1 to 85.8) | 27.6 (21.8 to 33.9) |
| Serotype 15C | 77.8 (71.8 to 83.0) | 61.3 (54.6 to 67.7) |
| Serotype 16F | 80.4 (74.7 to 85.4) | 8.0 (4.8 to 12.4) |
| Serotype 23A | 76.9 (70.8 to 82.2) | 14.7 (10.3 to 20.0) |
| Serotype 23B | 72.9 (66.6 to 78.6) | 35.6 (29.3 to 42.2) |
| Serotype 24F | 87.6 (82.5 to 91.6) | 0.0 (0.0 to 1.6) |
| Serotype 31 | 75.6 (69.4 to 81.0) | 7.6 (4.5 to 11.8) |
| Serotype 35B | 84.0 (78.5 to 88.5) | 0.9 (0.1 to 3.2) |
| Serotype 6C | 29.8 (23.9 to 36.2) | 6.7 (3.8 to 10.8) |
| Serotype 15B | 60.4 (53.7 to 66.9) | 65.3 (58.7 to 71.5) |
Collected over Up to approximately 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| V116 | 0/225 (0%) | 1/225 (0.4%) | 77/225 (34.2%) |
| PPSV23 | 0/225 (0%) | 0/225 (0%) | 96/225 (42.7%) |
| Event | V116 | PPSV23 |
|---|---|---|
| Lacunar infarctionNervous system disorders | 1/225 | 0/225 |
| Event | V116 | PPSV23 |
|---|---|---|
| Injection site painGeneral disorders | 60/225 | 81/225 |
| FatigueGeneral disorders | 15/225 | 25/225 |
| Injection site erythemaGeneral disorders | 19/225 | 24/225 |
| Injection site swellingGeneral disorders | 14/225 | 17/225 |
| Age, Continuous(Years) | V116 | PPSV23 | Total |
|---|---|---|---|
| Mean | 70.9 ± 5.7 | 70.9 ± 5.6 | 70.9 ± 5.7 |
| Sex: Female, Male(Participants) | V116 | PPSV23 | Total |
|---|---|---|---|
| Female | 99 | 96 | 195 |
| Male | 126 | 129 | 255 |
| Ethnicity (NIH/OMB)(Participants) | V116 | PPSV23 | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 225 | 225 | 450 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | V116 | PPSV23 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 225 | 225 | 450 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT)(Titers) | V116 | PPSV23 | Total |
|---|---|---|---|
| Serotype 6A | 108.5 (19.5 to 3133) | 149.1 (19.5 to 9061) | 127.9 (19.5 to 9061) |
| Serotype 15A | 387.0 (21.0 to 9904) | 416.4 (21.0 to 9477) | 401.3 (21.0 to 9904) |
| Serotype 16F | 820.5 (78.0 to 25880) | 757.9 (78.0 to 25880) | 787.8 (78.0 to 175891) |
| Serotype 23A | 324.0 (21.0 to 14131) | 344.8 (21.0 to 7126) | 333.9 (21.0 to 14131) |
| Serotype 23B | 36.6 (5.0 to 4303) | 41.2 (5.0 to 4834) | 38.9 (5.0 to 4834) |
| Serotype 24F | 627.6 (10.5 to 10682) | 641.9 (10.5 to 8032) | 634.6 (10.5 to 10682) |
| Serotype 31 | 129.0 (8.0 to 3765) | 176.5 (8.0 to 71474) | 151.0 (8.0 to 71474) |
| Serotype 35B | 852.6 (12.0 to 12052) | 937.0 (12.0 to 11378) | 893.7 (12.0 to 12052) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Jan 2023 to primary completion in May 2023, 4 months.
Results were first posted in May 2024, 1 year after primary completion.
Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 4 months is below that.
Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pneumococcal 21-Valent Conjugate Vaccine